Aubry
Senior Member
- Messages
- 191
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4854652/#!po=31.3333
C respresents inflamed dentric cells of the gut before and after administration of Ruxolitinib (the purple grapes are inflamed cells). This is causing probably the abnormalities seen in the micro biome of all ME/CFS patients.Since the micro biome is more and more investigated this could be very interesting for ME/CFS as well. Prof. Meirleir will start trials in 2018 with Filgotinib (another JAK inhibitor) in his patient groups.
Skin and intestinal GvHD responds to ruxolitinib
C respresents inflamed dentric cells of the gut before and after administration of Ruxolitinib (the purple grapes are inflamed cells). This is causing probably the abnormalities seen in the micro biome of all ME/CFS patients.Since the micro biome is more and more investigated this could be very interesting for ME/CFS as well. Prof. Meirleir will start trials in 2018 with Filgotinib (another JAK inhibitor) in his patient groups.
Skin and intestinal GvHD responds to ruxolitinib